Auorua Cannabis Inc (TSE:ACB), Canopy Growth Corp (TSE:WEED), Aphria Inc (TSE:APH), MedReleaf Corp: Canada Cannabis Roundup

James West
|

Aurora Cannabis Inc (TSE:ACB) (OTCQB:ACBFF) (FRA:21P), Canopy Growth Corp (TSE:WEED) (OTCMKTS:TWMJF) (FRA:11L1), Aphria Inc (TSE:APH) (OTCMKTS:APHQF) (FRA:10E) and MedReleaf Corp (TSE:LEAF) (OTCMKTS:MEDFF) (FRA:MEW) all issued news on Monday April 16th to kick of Canada’s red-hot cannabis sector today.

Canopy Growth announced they had received licenses at their BC Tweed Joint Venture operations that will see the company’s licensed production area at the 1.3 million square foot greenhouse in Aldergrove, BC, upgraded to 840,000 square feet, and its 1.7 million square foot operation now licensed to 900,000 square feet of growing capacity, now the world’s largest single location cannabis facility on the planet. Total production capacity for Canopy Growth is now 2.4 million square feet.

Bruce Linton, CEO of Canopy Growth Corp, the world’s largest cannabis company, outlines his plans for Cananbis global domination.

This followed Sunday’s news on the acquisition fo the largest cannabis production operation in the Czech Republic of Annabis Meidical s.r.o.

MedReleaf announced that it had added “PINs” or “Product Identification Numbers, which are along the same lines as “Drug Identification Numbers” or “DINs” that facilitate the ability of participants and insurers in group benefits programs to claim MedReleaf’s cannabis products under those programs.

“We have extensive experience in developing programs to support large patient groups and we are encouraged by the growing interest we are seeing from employers and payers in covering medical cannabis products,” noted Neil Closner, CEO of MedReleaf.

Neil Closner, CEO of MedReleaf Corp, discusses his company’s focus on the medical cannabis market and pharmaceutical standardization as the cornerstone of his company’s value proposition for cannabis investors.

Aphria published Q3 2018 reuslts today, showing net income of $12.9 million on revenue of $10.3 million (there’s the amazing ability of IFRS defective accounting standard that enable biological assets to put net revenue ahead of gross revenue!).

The company reported total sales of 1,428,000 kilograms with an all-in cash cost per gram of $1.56, down from $2.13 per gram over in Q2.

Vic Neufeld, CEO of Aphria Inc., describes his company’s ongoing global expansion into Europe with its acquisition of Nuuvera.

The company continues to report positive EBITDA for the 10th consecutive quarter and is on track to complete a 700,000 square foot expansion, as well as to refit a 1.3 million square foot retrofit project at its Double Diamond Farms project.

Aurora Cannabis announced it had partnered with CTT Pharmaceuticals through its acquisition of Cannimed Therapeutics to distribute CTT’s drug delivery technologies, that provide the ability to deliver pharmaceutical agents (like cannabinoids) on “paper-thin polymer films”. (think Listerine Breath Strips)

According to the press release, there are 6 patents associated with the deal.

Dr. Pankaj Modi, CEO of CTT Pharma, added, “We are excited about the growth potential that our exclusive Canadian partnership with CanniMed and Aurora offers. Their large and rapidly growing patient base, both in Canada and around the world represent a significant distribution opportunity for our sub-lingual wafer technology, and with the establishment of CanniMed as the heart of Aurora’s Medical Cannabis Centre of Excellence, we anticipate that Aurora’s proven track record of execution will accelerate market development for our products.”

More Cannabis Stocks Stories

VIDEO: Khiron Life Sciences Inc: The Next Cannabis Company to Invest in Could be in Colombia

Aurora Cannabis Inc (TSE:ACB) Integration of Hempco Food and Fiber Inc (CVE:HEMP) Boosts Price

VIDEO: UIT Fund Manager Charles Taerk on CannTrust Holdings Inc, Cronos Group, and MedReleaf Corp

VIDEO: International Cannabis Solutions CEO Kevin Hall Educating the Workplace for Cannabis

James West

James West

Editor and Publisher

I employ a Capital Efficiency Model that dictates money should never be exposed for longer than is absolutely necessary to the possibility of being lost. Thus, I routinely sell half my position when a stock doubles from my entry price, and I sell stocks that lose 20%, unless there are...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!